Clinical Trials · NCT00001860

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment
5
Start date
Aug 1999
Locations
1 site, United States
Primary endpoint
Study in Acromegaly
View Octreotide compound reference